Critical Comparison: MariMed (MRMD) versus Its Competitors

MariMed (OTC:MRMD) is one of 55 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare MariMed to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation.

Risk & Volatility

MariMed has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, MariMed’s rivals have a beta of 1.27, suggesting that their average stock price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for MariMed and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	0	0	1	4.00
MariMed Competitors	291	567	1085	86	2.48

As a group, “Medicinals & botanicals” companies have a potential upside of 83.10%. Given MariMed’s rivals higher probable upside, analysts clearly believe MariMed has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares MariMed and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MariMed	$148.60 million	-$16.03 million	-2.42
MariMed Competitors	$310.11 million	-$49.81 million	-5.22

MariMed’s rivals have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MariMed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.95%	1.58%	0.53%
MariMed Competitors	-38.94%	-24.68%	-6.33%

Insider & Institutional Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 15.8% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 19.0% of MariMed shares are owned by insiders. Comparatively, 21.5% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

MariMed beats its rivals on 8 of the 13 factors compared.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.